TB-500

Product Overview

TB-500 5 mg by Zyvex Pharmaceuticals is supplied as a vial labeled with 5 mg of a Thymosin Beta-4-related peptide. TB-500 products are commonly marketed in regenerative and sports-recovery contexts because thymosin beta-4 biology is associated with actin regulation, cell migration, tissue remodeling, angiogenic signaling, and wound-healing research.

An important pharmacological distinction is necessary. Full-length Thymosin Beta-4 (Tβ4) and TB-500 are not necessarily identical substances. FDA's substance registry identifies TB-500 specifically as the N-terminal acetylated 17–23 fragment of thymosin beta-4, also described as N-acetyl-LKKTETQ. Therefore, a commercial product labeled simultaneously as "TB-500" and "Thymosin Beta-4" requires appropriate analytical characterization to establish which molecular species it actually contains.

Full-length thymosin beta-4 has undergone limited human clinical research, including intravenous and topical investigations. In contrast, FDA's 2026 review of TB-500 specifically reported that it did not identify published studies in which the TB-500 fragment itself had been administered to humans.

Neither TB-500 nor independently supplied injectable Thymosin Beta-4 products should be represented as FDA-approved treatments for tendon injuries, ligament injuries, muscle tears, wound healing, athletic recovery, or bodybuilding.

The 5 mg designation describes stated vial content. It does not establish a medically approved injection dose, administration frequency, or treatment course.

Product Class

• Investigational thymosin-related peptide
• Thymosin beta-4-derived research compound
• Actin-associated regenerative research peptide
• Experimental tissue-remodeling compound
• Wound-healing research peptide
• Non-androgenic compound
• Non-SARM compound
• Non-growth-hormone secretagogue

Indications

Clinical and Research Context

Thymosin beta-4 biology has generated scientific interest because of its relationship with actin, cell motility, tissue repair, vascular responses, and inflammatory signaling. Experimental programs involving full-length thymosin beta-4 have examined areas such as wound repair and cardiovascular tissue injury.

Potential research areas include:

• Wound repair
• Cell migration
• Tissue remodeling
• Angiogenic signaling
• Inflammatory regulation
• Corneal and epithelial repair
• Cardiovascular tissue-protection research

These biological observations should not be extrapolated automatically to a commercial TB-500 vial. FDA's July 2026 scientific review emphasized that published human exposure data for the TB-500 fragment were not identified and that evidence supporting proposed wound-healing use was inadequate.

Performance and Recovery Context

TB-500 is widely discussed outside conventional medicine for:

• Tendon recovery
• Ligament recovery
• Muscle-injury recovery
• Mobility following soft-tissue injury
• Wound healing
• Recovery between training sessions
• Connective-tissue support

These remain investigational or non-medical applications. There is insufficient controlled human evidence demonstrating that TB-500 injections accelerate healing of sports-related tendon, ligament, or muscle injuries.

TB-500 is also not a direct anabolic agent. It does not activate androgen receptors in the manner of Testosterone, Trenbolone, Oxandrolone, or other anabolic-androgenic steroids.

Mechanism of Action

Full-length Thymosin Beta-4 is a naturally occurring peptide strongly associated with regulation of actin dynamics. Actin is an essential structural protein involved in cellular architecture, movement, migration, and tissue-remodeling processes.

Thymosin beta-4 binds monomeric G-actin and contributes to regulation of actin polymerization. Experimental research has consequently linked thymosin beta-4 biology with:

• Cell migration
• Cytoskeletal organization
• Fibroblast activity
• Extracellular-matrix remodeling
• Angiogenic signaling
• Inflammatory responses
• Epithelial repair
• Tissue regeneration pathways

TB-500, as characterized by FDA, is an acetylated seven-amino-acid fragment derived from residues 17–23 of thymosin beta-4. This region contains the LKKTET actin-binding sequence associated with important aspects of full-length thymosin beta-4 biology.

However, possessing a sequence derived from an active region does not demonstrate that the fragment reproduces all pharmacological actions of the complete 43-amino-acid thymosin beta-4 molecule. Full-length Tβ4 research therefore cannot automatically be treated as evidence for commercial TB-500.

Potential Benefits

The potential benefits associated with thymosin beta-4-related compounds are predominantly based on experimental regenerative biology rather than established therapeutic use of TB-500.

Areas of scientific interest include:

• Support of cellular migration during tissue repair
• Modulation of actin-dependent cellular processes
• Wound-remodeling pathways
• Potential vascular and angiogenic responses
• Inflammatory signaling
• Soft-tissue regeneration research
• Epithelial and connective-tissue repair

Claims that TB-500 reliably heals torn tendons, regenerates ligaments, repairs muscle injuries, dramatically increases flexibility, or accelerates return to sport are not supported by adequate controlled human clinical evidence.

Likewise, TB-500 should not be described as directly increasing muscle protein synthesis in the manner of an anabolic steroid. Any proposed recovery-related effects belong to regenerative and cell-migration research rather than classical androgen-mediated muscle anabolism.

Synergy & Stacking

TB-500 is frequently discussed alongside other investigational regenerative compounds. Such combinations are not validated treatment protocols.

• BPC-157: An investigational pentadecapeptide commonly discussed in tendon, gastrointestinal, and tissue-repair contexts. Human safety and efficacy data remain highly limited.
• GHK-Cu: A copper-binding tripeptide associated with extracellular-matrix, skin, and wound-remodeling research.
• Growth Hormone: An established endocrine hormone with approved medical indications that acts through the GH/IGF-1 axis rather than thymosin pathways.
• Ipamorelin: Investigational growth-hormone secretagogue acting at the ghrelin/GHS-R1a receptor.
• CJC-1295: Investigational GHRH analogue that stimulates growth-hormone signaling through a different receptor mechanism.

The frequently discussed BPC-157 plus TB-500 combination has not been validated in controlled human trials as a standardized tendon- or ligament-healing protocol.

Combining several experimental peptides can also make it difficult to determine which compound is responsible for either an apparent benefit or an adverse event. It additionally increases uncertainty concerning sterility, identity, peptide purity, aggregation, and immune responses.

HRT/TRT Application

TB-500 has no established role in Hormone Replacement Therapy or Testosterone Replacement Therapy.

It does not:

• Supply testosterone
• Activate androgen receptors as its primary mechanism
• Replace physiological androgen deficiency
• Function as a SERM
• Function as an aromatase inhibitor
• Directly stimulate LH or FSH
• Serve as a growth-hormone replacement product

TB-500 is therefore fundamentally different from Testosterone Enanthate, Testosterone Cypionate, Sustanon, or other androgen-replacement formulations.

Because it is non-androgenic, classical androgen-mediated suppression of the hypothalamic-pituitary-gonadal axis is not an expected primary pharmacological action. Nevertheless, the systemic safety profile of independently supplied injectable TB-500 remains inadequately characterized.

Dosing and Use

TB-500 by Zyvex Pharmaceuticals is labeled as containing 5 mg per vial. The vial strength identifies stated total product content only.

There is no FDA-approved human dosing regimen for injectable TB-500 for tendon repair, muscle injuries, ligament injuries, bodybuilding, athletic recovery, or general regenerative use.

Accordingly, the 5 mg vial should not automatically be interpreted as:

• A single injection dose
• A weekly dose
• A loading dose
• A maintenance dose
• A complete treatment course
• A validated sports-recovery protocol

Published clinical investigations involving full-length thymosin beta-4 should also not be converted directly into dosing instructions for TB-500 because the two molecular entities are not necessarily equivalent.

For injectable peptide products, clinically relevant quality considerations include molecular identity, purity, peptide-related impurities, aggregation, sterility, bacterial endotoxin, particulate contamination, concentration accuracy, and stability after preparation.

FDA has specifically identified immunogenicity and peptide-related impurity concerns with TB-500-related compounded products and has stated that important human safety information is lacking.

Female Use

TB-500 is not an androgen-receptor agonist and therefore is not expected to produce the classic virilization pattern associated with anabolic-androgenic steroids.

Androgen-related effects such as:

• Voice deepening
• Clitoral enlargement
• Male-pattern facial-hair development
• Androgenic scalp-hair loss

are not expected from the proposed thymosin-related mechanism itself.

However, the absence of androgenicity should not be confused with established safety. Human systemic exposure data for TB-500 remain inadequate, and reproductive, pregnancy, fetal-development, and breastfeeding safety have not been sufficiently established.

The 5 mg vial strength does not represent a validated female dose.

Comparative Analysis

TB-500 vs Full-Length Thymosin Beta-4

• TB-500: FDA identifies this substance as an acetylated 17–23 fragment of thymosin beta-4 containing seven amino acids.
• Thymosin Beta-4: Naturally occurring full-length peptide consisting of 43 amino acids.
• They share sequence-related biology but should not automatically be treated as identical compounds.
• Human studies of full-length Tβ4 do not establish equivalent safety or efficacy for TB-500.

TB-500 vs BPC-157

• TB-500: Thymosin beta-4-derived peptide associated with actin and cell-migration research.
• BPC-157: Synthetic 15-amino-acid peptide investigated primarily in preclinical tissue and gastrointestinal models.
• Both are commonly marketed for recovery despite insufficient evidence supporting established injectable treatment protocols.

TB-500 vs GHK-Cu

• TB-500: Thymosin-related peptide associated with actin-dependent cell migration.
• GHK-Cu: Copper-binding tripeptide associated with extracellular-matrix and tissue-remodeling research.
• Neither is an anabolic steroid or SARM.

TB-500 vs Growth Hormone

• TB-500: Investigational regenerative peptide associated with actin and cellular migration.
• Growth Hormone: Endocrine hormone acting primarily through GH receptor signaling and downstream IGF-1.
• Approved recombinant GH has established clinical indications; TB-500 does not have an equivalent approved therapeutic role.

TB-500 vs Ipamorelin

• TB-500: Thymosin-related regenerative research peptide.
• Ipamorelin: Ghrelin/GHS-R1a receptor agonist that stimulates endogenous growth-hormone secretion.
• Their mechanisms are fundamentally different.

TB-500 vs Anabolic Steroids

TB-500 does not primarily activate androgen receptors and does not function as an anabolic-androgenic steroid. Performance interest centers on proposed tissue-repair and recovery effects rather than direct androgen-mediated hypertrophy.

Conclusion

TB-500 5 mg by Zyvex Pharmaceuticals is supplied as a vial labeled with a thymosin beta-4-related active substance. TB-500 belongs to an investigational class of peptides associated with actin regulation, cell migration, wound remodeling, and regenerative research.

A key scientific distinction exists between full-length Thymosin Beta-4 and the TB-500 fragment. FDA identifies TB-500 as the acetylated 17–23 fragment of thymosin beta-4 and reported in its 2026 evaluation that published human administration studies of this specific fragment were not identified. Human studies involving full-length thymosin beta-4 therefore should not automatically be used to establish the clinical efficacy or safety of TB-500.

TB-500 is not an anabolic steroid, SARM, TRT product, or growth-hormone secretagogue. Claims concerning accelerated tendon, ligament, muscle, or wound healing remain insufficiently validated in controlled human trials. The 5 mg designation describes stated vial content rather than an approved dose or sports-recovery protocol.